{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T22:19:07Z","timestamp":1774563547778,"version":"3.50.1"},"publisher-location":"Chichester, UK","reference-count":85,"publisher":"John Wiley & Sons, Ltd","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1002\/14651858.cd002203.pub2","type":"reference-entry","created":{"date-parts":[[2004,4,23]],"date-time":"2004-04-23T13:01:47Z","timestamp":1082725307000},"source":"Crossref","is-referenced-by-count":43,"title":["Macrolide antibiotics for cystic fibrosis"],"prefix":"10.1002","author":[{"given":"Kevin W","family":"Southern","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre M","family":"Barker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arturo","family":"Solis-Moya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Latifa","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2004,4,19]]},"reference":[{"issue":"10","key":"10.1002\/14651858.CD002203.pub2-BIB2|cit1","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1136\/thx.2005.057950","article-title":"Long term effects of azithromycin in patients with cystic fibrosis: a double-blind, placebo-controlled trial","volume":"61","author":"Clement","year":"2006","journal-title":"Thorax"},{"issue":"Suppl 28","key":"10.1002\/14651858.CD002203.pub2-BIB3|cit2","first-page":"285","article-title":"Long term effects and clinical outcome of low-dose azithromycin in young patients with cystic fibrosis: a multicenter, randomized, double-blind, placebo-controlled trial [abstract]","volume":"40","author":"Clement","year":"2005","journal-title":"Pediatric Pulmonology"},{"issue":"Suppl1","key":"10.1002\/14651858.CD002203.pub2-BIB1|cit3","first-page":"S68","article-title":"Long term effects and clinical outcome of low-dose azithromycin in young patients with cystic fibrosis: a mulicenter, randomized, double-blind, placebo-controlled trial [abstract]","volume":"4","author":"Clement","year":"2005","journal-title":"Journal of Cystic Fibrosis"},{"issue":"9338","key":"10.1002\/14651858.CD002203.pub2-BIB4|cit4","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/S0140-6736(02)11081-6","article-title":"Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial","volume":"360","author":"Equi","year":"2002","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD002203.pub2-BIB5|cit5","first-page":"307","article-title":"A prospective, double-blind, randomised, placebo controlled, crossover trial of long term azithromycin in children [abstract]","volume":"Suppl 22","author":"Equi","year":"2001","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD002203.pub2-BIB6|cit6","first-page":"iii38","article-title":"A prospective, double-blind, randomised, placebo controlled, crossover trial of azithromycin in paediatric cystic fibrosis [abstract]","volume":"Suppl 3","author":"Equi","year":"2002","journal-title":"Thorax"},{"issue":"1","key":"10.1002\/14651858.CD002203.pub2-BIB7|cit7","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jcf.2009.09.001","article-title":"Long-term daily high and low doses of azithromycin in children with cystic fibrosis: a randomized controlled trial","volume":"9","author":"Kabra","year":"2010","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD002203.pub2-BIB8|cit8","unstructured":"Bell S Serisier D Wainwright C Bowler S Senini S Walmsley K 6-month treatment with azithromycin reduces hospital admissions for respiratory exacerbations in cystic fibrosis [abstract] Respirology 2006 A58"},{"key":"10.1002\/14651858.CD002203.pub2-BIB9|cit9","unstructured":"Bell S Serisier D Wainwright C Bowler S Senini S Walmsley K Randomised, prospective double-blind trial of long term daily versus weekly azithromycin in cystic fibrosis [abstract] Respirology 2006 A11"},{"issue":"3","key":"10.1002\/14651858.CD002203.pub2-BIB10|cit10","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1183\/09031936.00163306","article-title":"Daily versus weekly azithromycin in cystic fibrosis patients","volume":"30","author":"McCormack","year":"2007","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD002203.pub2-BIB11|cit11","unstructured":"Senini S McCormack J A randomised, prospective double-blind trial of long-term daily versus weekly azithromycin in cystic fibrosis Australian New Zealand Clinical Trials Registry (www.anzctr.org.au) (accessed 04 March 2010) 2005"},{"key":"10.1002\/14651858.CD002203.pub2-BIB13|cit12","volume-title":"The use of azithromycin in cystic fibrosis patients not infected with Pseudomonas aeruginosa","author":"O'Connor","year":"2009"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD002203.pub2-BIB12|cit13","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1016\/S1569-1993(08)60095-8","article-title":"Use of azithromycin in cystic fibrosis patients not infected with Pseudomonas aeruginosa [abstract]","volume":"7","author":"O'Connor","year":"2008","journal-title":"Journal of Cystic Fibrosis"},{"issue":"2","key":"10.1002\/14651858.CD002203.pub2-BIB14|cit14","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1007\/s10238-005-0070-7","article-title":"Autoantibodies against bactericidal\/permeability-increasing protein (BPI-ANCA) in cystic fibrosis patients treated with azithromycin","volume":"5","author":"Rotschild","year":"2005","journal-title":"Clinical and Experimental Medicine"},{"issue":"Suppl 27","key":"10.1002\/14651858.CD002203.pub2-BIB15|cit15","first-page":"286","article-title":"Phenotypic characterization of pseudomonas aeruginosa as a potential predictor of clinical response to azithromycin in CF patients [abstract]","volume":"38","author":"Nguyen","year":"2004","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD002203.pub2-BIB18|cit16","first-page":"165","article-title":"What have we learned from further analysis of the U.S. Macrolide Trial?: Subgroup analysis of azithromycin trial [abstract]","volume":"36 Suppl 25","author":"Saiman","year":"2003","journal-title":"Pediatric Pulmonology"},{"issue":"13","key":"10.1002\/14651858.CD002203.pub2-BIB16|cit17","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1001\/jama.290.13.1749","article-title":"Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial","volume":"290","author":"Saiman","year":"2003","journal-title":"JAMA"},{"issue":"8","key":"10.1002\/14651858.CD002203.pub2-BIB17|cit18","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1164\/rccm.200502-218OC","article-title":"Heterogeneity of treatment response to azithromycin in patients with cystic fibrosis","volume":"172","author":"Saiman","year":"2005","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"32","key":"10.1002\/14651858.CD002203.pub2-BIB20|cit19","first-page":"185","article-title":"Azithromycin in CF patients uninfected with pseudomonas aeruginosa [abstract]","volume":"44","author":"Saiman","year":"2009","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD002203.pub2-BIB19|cit20","unstructured":"Saiman L Anstead M Ratjen F Lands L Effect of azithromycin on lung function in 6-18 year-olds with cystic fibrosis (CF) who are not infected with P. aeruginosa www.clinicaltrials.gov (accessed 04 March 2010) 2007"},{"issue":"11","key":"10.1002\/14651858.CD002203.pub2-BIB21|cit21","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1016\/j.rmed.2008.03.009","article-title":"Once-weekly azithromycin in cystic fibrosis with chronic Pseudomonas aeruginosa infection","volume":"102","author":"Steinkamp","year":"2008","journal-title":"Respiratory Medicine"},{"issue":"Suppl 30","key":"10.1002\/14651858.CD002203.pub2-BIB22|cit22","first-page":"300","article-title":"Once weekly azithromycin in cystic fibrosis: a double-blind, randomised trial in patients with chronic pseudomonas aeruginosa infection [abstract]","volume":"42","author":"Steinkamp","year":"2007","journal-title":"Pediatric Pulmonology"},{"issue":"Suppl","key":"10.1002\/14651858.CD002203.pub2-BIB23|cit23","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1016\/S1569-1993(06)80098-6","article-title":"Clinical and immunomodulatory effects of once weekly azithromycin treatment in cystic fibrosis patients chronically infected with pseudomonas aeruginosa [abstract]","volume":"5","author":"Steinkamp","year":"2006","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD002203.pub2-BIB24|cit24","first-page":"289","article-title":"Long-term treatment with azithromycin results in reduced ex-vivo inflammatory cytokine production in adults with cystic fibrosis [abstract]","volume":"34 Suppl 24","author":"Bell","year":"2002","journal-title":"Pediatric Pulmonology"},{"issue":"Suppl A","key":"10.1002\/14651858.CD002203.pub2-BIB27|cit25","first-page":"38","article-title":"Effect of long-term treatment with azithromycin on disease parameters in cystic fibrosis [abstract]","volume":"56","author":"Bowler","year":"2003","journal-title":"Japanese Journal of Antibiotics"},{"key":"10.1002\/14651858.CD002203.pub2-BIB25|cit26","first-page":"280","article-title":"A prospective, randomised trial of long term azithromycin (AZM) versus placebo in cystic fibrosis; impact on clinical, laboratory and quality of life (QOL) outcomes [abstract]","volume":"30 Suppl 20","author":"Bowler","year":"2000","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD002203.pub2-BIB26|cit27","first-page":"A9","article-title":"Long term treatment with azithromycin results in reduced in vitro inflammatory cytokine production in adults with cystic fibrosis [abstract]","volume":"7 Suppl 1","author":"Bowler","year":"2002","journal-title":"Respirology"},{"key":"10.1002\/14651858.CD002203.pub2-BIB28|cit28","first-page":"A12","article-title":"A prospective randomised trial of long term azithromycin (AZM) versus placebo in cystic fibrosis (CF): impact on clinical, laboratory and quality of life (QOL) outcomes [abstract]","volume":"31 Suppl","author":"Seeney","year":"2001","journal-title":"Internal Medicine Journal"},{"issue":"3","key":"10.1002\/14651858.CD002203.pub2-BIB29|cit29","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1136\/thorax.57.3.212","article-title":"Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial","volume":"57","author":"Wolter","year":"2002","journal-title":"Thorax"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD002203.pub2-BIB31|cit30","first-page":"157","article-title":"Clinical evidence for combination antibiotic susceptibility testing (synergy testing) [abstract]","volume":"43","author":"Aaron","year":"2008","journal-title":"Pediatric Pulmonology"},{"issue":"Suppl 28","key":"10.1002\/14651858.CD002203.pub2-BIB30|cit31","first-page":"304","article-title":"Treatment of CF exacerbations based on multiple combination antibiotic susceptibility testing-a randomized, double-blind, controlled clinical trial [abstract]","volume":"40","author":"Aaron","year":"2005","journal-title":"Pediatric Pulmonology"},{"issue":"9484","key":"10.1002\/14651858.CD002203.pub2-BIB32|cit32","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/S0140-6736(05)67060-2","article-title":"Combination antibiotic susceptibility testing to treat exacerbations of cystic fibrosis associated with multiresistant bacteria: a randomised, double-blind, controlled clinical trial","volume":"366","author":"Aaron","year":"2005","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD002203.pub2-BIB33|cit33","first-page":"283","article-title":"Effect of chronic azithromycin on lung function in cystic fibrosis","volume":"28 Suppl 19","author":"Anstead","year":"1999","journal-title":"Pediatric Pulmonology"},{"issue":"5 Suppl","key":"10.1002\/14651858.CD002203.pub2-BIB34|cit34","first-page":"A565","article-title":"Effect of azithromycin on lung function, sputum bacteriology, and sputum inflammatory markers in cystic fibrosis [abstract]","volume":"163","author":"Anstead","year":"2001","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"3 Suppl","key":"10.1002\/14651858.CD002203.pub2-BIB35|cit35","first-page":"A758","article-title":"The effects of azithromycin therapy on sputum inflammation in CF lung disease [abstract]","volume":"161","author":"App","year":"2000","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD002203.pub2-BIB36|cit36","first-page":"S130","article-title":"Low-dose azithromycin therapy reaches sputum drug levels of potential antipseudomonal activity in cystic fibrosis patients [abstract]","volume":"1","author":"Baumann","year":"2002","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD002203.pub2-BIB37|cit37","series-title":"Proceedings of the 13th International Cystic Fibrosis Congress; 2000 June 4-8; Stockholm","first-page":"164","article-title":"Sputum DNA under long-term therapy with azithromycin [abstract]","author":"Baumann","year":"2000"},{"key":"10.1002\/14651858.CD002203.pub2-BIB38|cit38","series-title":"Proceedings of the 13th International Cystic Fibrosis Congress;2000 June 4-8; Stockholm","first-page":"165","article-title":"Long-term low-dose therapy with azithromycin in CF [abstract]","author":"Baumann","year":"2000"},{"issue":"12","key":"10.1002\/14651858.CD002203.pub2-BIB39|cit39","doi-asserted-by":"crossref","first-page":"5013","DOI":"10.1128\/AAC.49.12.5013-5017.2005","article-title":"Absolute bioavailability and intracellular pharmacokinetics of azithromycin in patients with cystic fibrosis","volume":"49","author":"Beringer","year":"2005","journal-title":"Antimicrobial agents and chemotherapy"},{"issue":"Suppl 27","key":"10.1002\/14651858.CD002203.pub2-BIB40|cit40","first-page":"285","article-title":"Controlled pharmacokinetic study of azithromycin in adult cystic fibrosis patients [abstract]","volume":"38","author":"Beringer","year":"2004","journal-title":"Pediatric Pulmonology"},{"issue":"5","key":"10.1002\/14651858.CD002203.pub2-BIB41|cit41","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2165\/00044011-200121050-00005","article-title":"Azithromycin concentrations in serum and bronchial secretions of patients with cystic fibrosis","volume":"21","author":"Cipolli","year":"2001","journal-title":"Clinical Drug Investigation"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD002203.pub2-BIB42|cit42","first-page":"S24","article-title":"Laboratory and clinical effect of long-term roxithromycin treatment in adult patients with cystic fibrosis [abstract]","volume":"4","author":"Dionyssopoulou","year":"2005","journal-title":"Journal of Cystic Fibrosis"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD002203.pub2-BIB43|cit43","first-page":"S21","article-title":"Effect of clarithromycin on inflammatory markers in bronchoalveolar lavage fluid in cystic fibrosis: a randomised, placebo-controlled crossover trial [abstract]","volume":"3","author":"Dogru","year":"2004","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD002203.pub2-BIB44|cit44","series-title":"Abstracts of the 24th European Cystic Fibrosis Conference; 2001 June 6-9; Vienna","first-page":"P208","article-title":"Clinical efficacy of clarithromycin in CF patients with chronic lung infection [abstract]","author":"Frederiksen","year":"2001"},{"issue":"9100","key":"10.1002\/14651858.CD002203.pub2-BIB45|cit45","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/S0140-6736(05)78360-4","article-title":"Long-term azithromycin may improve lung function in children with cystic fibrosis","volume":"351","author":"Jaffe","year":"1998","journal-title":"Lancet"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD002203.pub2-BIB46|cit46","first-page":"S24","article-title":"Circulating phagocytes during Azithromycin treatment of Cystic Fibrosis patients with chronic Pseudomonas aeruginosa lung infection [abstract]","volume":"4","author":"Jensen","year":"2005","journal-title":"Journal of Cystic Fibrosis"},{"issue":"Suppl 45","key":"10.1002\/14651858.CD002203.pub2-BIB47|cit47","first-page":"514s","article-title":"Efficacy of low-dose, long-term clarithromycin administration in improving the clinical course in cystic fibrosis patients with chronic P. aeruginosa airway colonization [abstract]","volume":"22","author":"Kessaris","year":"2003","journal-title":"European Respiratory Journal"},{"issue":"1","key":"10.1002\/14651858.CD002203.pub2-BIB48|cit48","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/ppul.1085","article-title":"Effect of clarithromycin on airway obstruction and inflammatory markers in induced sputum in cystic fibrosis: a pilot study","volume":"32","author":"Ordonez","year":"2001","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD002203.pub2-BIB49|cit49","series-title":"Pediatric Pulmonology","first-page":"263","article-title":"Long term macrolide antibiotics improve pulmonary function in cystic fibrosis [abstract]","author":"Pirzada","year":"1999"},{"key":"10.1002\/14651858.CD002203.pub2-BIB50|cit50","first-page":"274","article-title":"Increase of the sputum neutrophil elastase activity is a paradoxical effect of the successful lung disease treatment in cystic fibrosis [abstract]","volume":"32 Suppl 22","author":"Pukhalsky","year":"2001","journal-title":"Pediatric Pulmonology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD002203.pub2-BIB51|cit51","first-page":"S31","article-title":"Long-term low-dose therapy with macrolides in bronchopulmonary disease in Cystic Fibrosis (CF) pediatric patients [abstract]","volume":"4","author":"Radionovitch","year":"2005","journal-title":"Journal of Cystic Fibrosis"},{"issue":"8","key":"10.1002\/14651858.CD002203.pub2-BIB52|cit52","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1164\/rccm.200311-1508OC","article-title":"Effect of macrolides on in vivo ion transport across cystic fibrosis nasal epithelium","volume":"171","author":"Barker","year":"2005","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD002203.pub2-BIB53|cit53","unstructured":"Rubin BK Macrolide antibiotic therapy for patients with cystic fibrosis www.clinicaltrials.gov (accessed 04 March 2010) 2005"},{"issue":"Suppl 48","key":"10.1002\/14651858.CD002203.pub2-BIB54|cit54","first-page":"P3758","article-title":"Anti-inflammatory therapy in cystic fibrosis: a comparative study in the treatment with nimesulide (selective cyclooxygenase-2 inhibitor) and clarithromycin (14-memebered ring macrolide antibiotic) [abstract]","volume":"24","author":"Shmarina","year":"2004","journal-title":"European Respiratory Journal"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD002203.pub2-BIB55|cit55","first-page":"S52","article-title":"The antiinflammatory effect of clarithromycin in CF [abstract]","volume":"2","author":"Sriram","year":"2003","journal-title":"Journal of Cystic Fibrosis"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD002203.pub2-BIB56|cit56","doi-asserted-by":"crossref","first-page":"S24, Abstract n","DOI":"10.1016\/S1569-1993(10)60093-8","article-title":"Adherence behaviour of adult cystic fibrosis (CF) patients to prescribed azithromycin [abstract]","volume":"9","author":"Elmasry","year":"2010","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD002203.pub2-BIB57|cit57","series-title":"European Respiratory Society Annual Congress; 2008 Oct 4-8; Berlin, Germany.","first-page":"216s","article-title":"Whether low frequency of hepatobiliary abnormalities in cystic fibrosis patients is associated with anti-inflammatory treatment? [abstract]","author":"Pukhalsky","year":"2008"},{"issue":"6","key":"10.1002\/14651858.CD002203.pub2-BIB58|cit58","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/BF01488805","article-title":"Membrane-stabilizing, anti-inflammatory interactions of macrolides with human neutrophils","volume":"20","author":"Anderson","year":"1996","journal-title":"Inflammation"},{"issue":"6","key":"10.1002\/14651858.CD002203.pub2-BIB59|cit59","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1177\/030006059101900603","article-title":"Azithromycin: an interim analysis","volume":"19","author":"Ball","year":"1991","journal-title":"Journal of International Medical Research"},{"issue":"Pt 3","key":"10.1002\/14651858.CD002203.pub2-BIB60|cit60","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1111\/j.1469-7793.1999.0631u.x","article-title":"Molecular insights into the physiology of the 'thin film' of airway surface liquid","volume":"516","author":"Boucher","year":"1999","journal-title":"Journal of Physiology"},{"issue":"15","key":"10.1002\/14651858.CD002203.pub2-BIB61|cit61","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1002\/sim.1205","article-title":"Meta-analysis combining parallel and cross-over clinical trials. I: Continuous outcomes","volume":"21","author":"Curtin","year":"2002","journal-title":"Statistics in Medicine"},{"issue":"15","key":"10.1002\/14651858.CD002203.pub2-BIB62|cit62","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1002\/sim.1206","article-title":"Meta-analysis combining parallel and cross-over clinical trials. II: Binary outcomes","volume":"21","author":"Curtin","year":"2002","journal-title":"Statistics in Medicine"},{"issue":"15","key":"10.1002\/14651858.CD002203.pub2-BIB63|cit63","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1002\/sim.1207","article-title":"Meta-analysis combining parallel and cross-over clinical trials. III: The issue of carryover","volume":"21","author":"Curtin","year":"2002","journal-title":"Statistics in Medicine"},{"issue":"6","key":"10.1002\/14651858.CD002203.pub2-BIB64|cit64","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.pupt.2009.03.002","article-title":"Effects of prolonged use of azithromycin in patients with cystic fibrosis: a meta-analysis","volume":"22","author":"Florescu","year":"2009","journal-title":"Pulmonary Pharmacology and Therapeutics"},{"issue":"1","key":"10.1002\/14651858.CD002203.pub2-BIB65|cit65","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jcf.2008.09.001","article-title":"Long-term, low-dose azithromycin treatment reduces the incidence but increases macrolide resistance in Staphylococcus aureus in Danish CF patients","volume":"8","author":"Hansen","year":"2009","journal-title":"Journal of Cystic Fibrosis"},{"issue":"7414","key":"10.1002\/14651858.CD002203.pub2-BIB66|cit66","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD002203.pub2-BIB67|cit67","doi-asserted-by":"crossref","unstructured":"Higgins JPT Altman DG on behalf of the Cochrane Statistical Methods Group and the Cochrane Bias Methods Group (editors) Chapter 8: \u00a0Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2009] The CochraneCollaboration, 2008. Available from www.cochrane-handbook.org","DOI":"10.1002\/9780470712184.ch8"},{"issue":"6","key":"10.1002\/14651858.CD002203.pub2-BIB68|cit68","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1136\/thx.49.6.531","article-title":"Diffuse panbronchiolitis and cystic fibrosis: East meets West","volume":"49","author":"Hoiby","year":"1994","journal-title":"Thorax"},{"issue":"12","key":"10.1002\/14651858.CD002203.pub2-BIB69|cit69","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/S1286-4579(99)80518-8","article-title":"Pathogenicity of microbes associated with cystic fibrosis","volume":"1","author":"Hutchison","year":"1999","journal-title":"Microbes and Infection"},{"issue":"3","key":"10.1002\/14651858.CD002203.pub2-BIB70|cit70","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1159\/000239440","article-title":"The influence of azithromycin on the biofilm formation of Pseudomonas aeruginosa in vitro","volume":"42","author":"Ichimiya","year":"1996","journal-title":"Chemotherapy"},{"key":"10.1002\/14651858.CD002203.pub2-BIB71|cit71","doi-asserted-by":"crossref","first-page":"S81","DOI":"10.1016\/0924-8579(93)90039-8","article-title":"Therapeutic possibilities for diffuse panbronchiolitis","volume":"3","author":"Kobayashi","year":"1993","journal-title":"International Journal of Antimicrobial Agents"},{"key":"10.1002\/14651858.CD002203.pub2-BIB72|cit72","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1093\/jac\/41.suppl_2.37","article-title":"Anti-inflammatory activity of macrolides: a new therapeutic potential?","volume":"41 Suppl B","author":"Labro","year":"1998","journal-title":"Journal Antimicrobial Chemotherapeutics"},{"issue":"7","key":"10.1002\/14651858.CD002203.pub2-BIB73|cit73","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/S0092-8674(00)81724-9","article-title":"Evidence for periciliary liquid layer depletion, not abnormal ion composition in the pathogenesis of cystic fibrosis airways disease","volume":"95","author":"Matsui","year":"1998","journal-title":"Cell"},{"issue":"3","key":"10.1002\/14651858.CD002203.pub2-BIB74|cit74","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1128\/AAC.38.3.528","article-title":"Comparative in vitro exoenzyme-suppressing activities of azithromycin and other macrolide antibiotics against Pseudomonas aeruginosa","volume":"38","author":"Mizukane","year":"1994","journal-title":"Antimicrobial Agents and Chemotherapy"},{"issue":"5","key":"10.1002\/14651858.CD002203.pub2-BIB75|cit75","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1093\/jac\/31.5.681","article-title":"Inhibition of Pseudomonas aeruginosa virulence factors by subinhibitory concentrations of azithromycin and other macrolide antibiotics","volume":"31","author":"Molinari","year":"1993","journal-title":"Journal of Antimicrobial Chemotherapy"},{"issue":"4","key":"10.1002\/14651858.CD002203.pub2-BIB76|cit76","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1093\/jac\/dkl014","article-title":"Macrolide resistance of Staphylococcus aureus and Haemophilus species associated with long-term azithromycin use in cystic fibrosis","volume":"57","author":"Phaff","year":"2006","journal-title":"Journal of Antimicrobial Chemotherapy"},{"issue":"12","key":"10.1002\/14651858.CD002203.pub2-BIB77|cit77","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1128\/AAC.31.12.1939","article-title":"Spectrum and mode of action of azithromycin (CP-62,993), a new 15-membered-ring macrolide with improved potency against gram-negative organisms","volume":"31","author":"Retsema","year":"1987","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1002\/14651858.CD002203.pub2-BIB78|cit78","unstructured":"The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2008"},{"issue":"4922","key":"10.1002\/14651858.CD002203.pub2-BIB79|cit79","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1126\/science.2475911","article-title":"Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA","volume":"245","author":"Riordan","year":"1989","journal-title":"Science"},{"issue":"3","key":"10.1002\/14651858.CD002203.pub2-BIB80|cit80","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD001912","article-title":"Prophylactic anti-staphylococcal antibiotics for cystic fibrosis","author":"Smyth","year":"2003","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD002203.pub2-BIB81|cit81","unstructured":"Steinkamp G (CF-Centre Hamburg-Altona and Clinical Research Hannover Germany) Email to KW Southern 2010"},{"issue":"1","key":"10.1002\/14651858.CD002203.pub2-BIB82|cit82","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/01.inf.0000247109.44249.ac","article-title":"Maintenance azithromycin treatment in pediatric patients with cystic fibrosis: long-term outcomes related to macrolide resistance and pulmonary function","volume":"26","author":"Tramper-Stranders","year":"2007","journal-title":"Pediatric Infectious Disease Journal"},{"issue":"1","key":"10.1002\/14651858.CD002203.pub2-BIB83|cit83","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1164\/ajrccm.155.1.9001333","article-title":"Effect of clarithromycin on lymphocytes in chronic respiratory Pseudomonas aeruginosa infection","volume":"155","author":"Yanagihara","year":"1997","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"2","key":"10.1002\/14651858.CD002203.pub2-BIB84|cit84","article-title":"Macrolide antibiotics for cystic fibrosis (Cochrane Review)","author":"Southern","year":"2003","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD002203.pub2-BIB85|cit85","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD002203.pub2","article-title":"Macrolide antibiotics for cystic fibrosis (Cochrane Review)","author":"Southern","year":"2004","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD002203.pub2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,13]],"date-time":"2024-01-13T05:21:52Z","timestamp":1705123312000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD002203.pub2"}},"subtitle":[],"editor":[{"given":"Kevin W","family":"Southern","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2004,4,19]]},"references-count":85,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd002203.pub2","relation":{},"subject":[],"published":{"date-parts":[[2004,4,19]]}}}